Pliant Therapeutics, Inc. filed a preliminary prospectus supplement for an underwritten public offering of its common stock, with an estimated cash position of $331.2 million as of December 31, 2022. They also entered into an underwriting agreement for the sale of 8,333,334 shares of common stock, expected to generate approximately $250.0 million in gross proceeds.